ArticleWorld journal of microbiology & biotechnology2025
Optimized solid lipid nanoparticles for co-delivery of gentamicin and doxycycline: a novel approach to combat intracellular brucella abortus infections.
Article in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanostructured Lipid Carriers Co-Loaded with Doxycycline, Gentamicin, and Thymol for Enhanced Intracellular Antibacterial Activity AgainstInternational journal of nanomedicine · 2026Article
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluates the potential of gentamicin (GEN) and doxycycline (DOX) co-loaded solid lipid nanoparticles (SLNs) for treating Brucella abortus infections. Optimized SLN formulations demonstrated mean particle sizes of 211.2 ± 10.8 nm, a polydispersity index of 0.42 ± 0.019, encapsulation efficiency of 95.3 ± 1.2%, and loading efficiency of 14.7 ± 0.1%. Drug release profiles revealed a biphasic release, achieving 91.1% and 73% cumulative release for GEN and DOX, respectively, over 72 h. In vitro studies on J774.A1 macrophages indicated significantly enhanced antibacterial activity and reduced cytotoxicity for SLN-GEN/DOX, achieving a minimum inhibitory concentration of 1.25 µg/mL and reducing intracellular bacterial load to 3.7 ± 0.02 Log
Indexed as
Identifiers
40571847What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.